Aegerion gains on Juxtapid sales

Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) shares jumped as much as 26% on Tuesday after the company reported $6.5 million in 2Q13 sales of Juxtapid lomitapide, beating the Street's estimate of $4.3 million. Aegerion has recorded $7.7 million in Juxtapid sales since launching the homozygous familial hypercholesterolemia (hoFH) drug in the U.S. early this year. The company said it expects to exceed its prior guidance of 250-300 patients on Juxtapid therapy by year end and raised its 2013 revenue guidance to $30-$35 million from $15-$25 million.

In May, EMA's CHMP recommended approval of an MAA for the small molecule microsomal triglyceride transfer protein (MTP) inhibitor under the name Lojuxta. Aegerion expects a final decision from the European Commission in August (see BioCentury Extra, May 31). ...